TheraCoat  Ltd. develops proprietary drug delivery systems for local treatment of internal cavities diseases. TheraCoat technology enables control on the pharmacokinetics of off-the-shelf drugs resulting in an optimized Therapeutic Index without changing the drug molecular structure.

TheraCoat is currently focused on local treatments of bladder diseases – such as non-muscle-invasive bladder cancer (NMIBC), upper tract urothelial carcinoma (UTUC) and overactive bladder (OAB) – treatments that together address over 300 million patients worldwide.

TheraCoat sustained release treatments enable controlled and longer exposure of bladder tissue to medications as compared to standard intravesical instillations. Pre-clinical results have shown over ten-fold higher drug concentration in the bladder tissue and significantly lower levels in the plasma, indicating a potential for significantly higher efficacy and better safety.

TheraCoat core capabilities are based on using a family of proprietary hydrogels that have ideal properties for deployment of medications into the bladder.

TheraCoat has commenced clinical studies of intravesical instillation with sustained release of chemotherapy for NMIBC and a neurotoxin for OAB.

TheraCoat has been granted CE Mark clearance as a Medical Device.

TheraCoat Pipeline